MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells
Sign Up to like & getrecommendations! Published in 2020 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-020-02456-x
Abstract: Background Glioblastoma (GB) remains an incurable and deadly brain malignancy that often proves resistant to upfront treatment with temozolomide. Nevertheless, temozolomide remains the most commonly prescribed FDA-approved chemotherapy for GB. The DNA repair protein methylguanine-DNA… read more here.
Keywords: cdk inhibitor; inhibitor; mgmt inhibitor; tgf inhibitor ... See more keywords